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Abstract
Background: Choice of dialysis is context sensitive, explored for PD and extracorporeal dialysis, but less studied for
haemodialysis (HD) and hemodiafiltration (HDF), both widely employed in Italy and France; reasons of choice and
differences in prescriptions may impact on dialysis-related variables, particularly relevant in elderly, high-comorbidity
patients.
Methods: The study involved two high-comorbidity in-hospital cohorts, treated in Centers with similar characteristics,
in Italy (Cagliari) and France (Le Mans). All patients (204) agreed to participate. Stable cases on thrice-weekly dialysis,
with at least 2 months follow-up were selected (180 patients, Males 59.4%, median age 71 years, vintage 4.3 years,
Charlson index 9). Univariate and multivariate correlations between baseline data, HD-HDF, dialysis efficiency and
nutritional markers were assessed.
Results: In Le Mans HDF was mainly chosen to increase efficiency (large surface dialysers, high convective volume; 76.3%
of the patients), in Cagliari to improve tolerance (smaller surfaces, lower convective volume; 59% of patients). Kt/V was
similar in HD and HDF, and in both settings(median Kt/V Daugirdas 2: 1.6); in the setting of high efficiency no correlation
was found between Kt/V, BMI, urea, creatinine, n-PCR and phosphate. The relationship between Kt/V and albumin was
divergent: a weak consensual increase was present in Cagliari, a decrease in Le Mans, suggesting a role of albumin losses
with high convective volumes. In the multivariate analysis, after adjustment for other covariates (including comorbidity
and type of treatment) low albumin level < 3.5 g/dl was highly correlated with setting of study: Le Mans
(OR: 7.155 (2.955–17.324)). The multivariate analysis confirmed a role of type of treatment, with higher risk
of low albumin levels in HDF (OR: 3.592 (1.466–8.801)), and of comorbidity (Charlson index> = 7 (OR: 3.153
(1.311–7.582)), MIS index> = 7 (OR: 5.916 (2.457–14.241)).
Conclusions: The different prescriptions of HD and HDF may have similar effects on dialysis efficiency, but diverging
effects on crucial nutritional markers, such as albumin levels, probably more evident in high-comorbidity populations.
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Background
The choice of dialysis is context sensitive, and while the
focus is usually on the treatment choice (peritoneal dia-
lysis versus extracorporeal dialysis, hemodialysis versus
hemodiafiltration), it is also acknowledged that results
do not only depend upon the treatment in itself, but
upon subtle differences in prescriptions and modalities.
Indeed, this issue has been extensively explored for PD
and extracorporeal dialysis, but less studied for haemodi-
alysis (HD) and hemodiafiltration (HDF) [1–5].
HF and HDF are widely employed in several European
Countries, including Italy and France; both treatments
may be differently prescribed, and for different goals,
thus impacting on dialysis-related variables; the impact
may be higher in elderly, high-comorbidity patients, with
high mortality at baseline [6–8]. Differences in prescrip-
tions, and not only in methods, may be at the basis of
the inconsistent results of comparisons between modes
of treatment, available in the literature [9, 10].
Hence, we undertook this cross-sectional study aimed at
exploring in detail the relationship between dialysis prescrip-
tions, selection criteria, dialysis efficiency and nutritional pa-
rameters in two relatively large cohorts of high-comorbidity
dialysis patients, treated with haemodialysis (HD) and
hemodiafiltration (HDF) in Italy and France.
The two centers where the study was undertaken
(Cagliari in Italy and Le Mans in France) are similar in a
number of ways: they are situated in relatively small cities,
with large, mainly rural, areas of referral, work in cooper-
ation with networks of out-of-hospital facilities, and share
a policy of selecting the patients with the highest comor-
bidity for in-hospital dialysis. Their policies on selecting
patients for HD and HDF are quite different, however.
While in Italy the criterion driving the choice of HDF is
its superior tolerance, in France it is its efficiency [9, 11].
It is hoped that the present study will help in the inter-
pretation of commonly used clinical markers in patients
with high comorbidity, treated by HDF or HD, favouring
comparison between dialysis policies, and ultimately casting
light on the specific influences of different prescriptions.
Methods
Settings and patients: Le Mans
The Centre Hospitalier du Mans (CHM), which is pres-
ently one of the three largest non- university hospitals in
France, has about 1700 beds, 500 in geriatric units and
about 300 for different medical specialties (at the time of
the study, 20 are in the nephrology unit).
Le Mans has about 150,000 inhabitants, with approxi-
mately another 150,000 people living in its suburbs;
CHM serves a population of about 800,000. Two dialysis
facilities run by a non-profit association (ECHO) are
present in the area but nephrology beds are only avail-
able at CHM.
The dialysis ward has 25 beds. These are occupied by
chronic dialysis patients, by patients with AKI (not needing
intensive care) as well as by patients from the out-of hospital
centers run by the ECHO who need to be hospitalized. The
pool of patients on chronic treatment ranges from 95 to
110, depending on the incidence of kidney transplantation,
death and transfers. In keeping with the indications of the
French Society of Nephrology (Société Francophone de
Néphrologie, Dialyse et Transplantation, SFNDT [12]),
out-of-hospital dialysis is widely used and only cases posing
particular clinical, attitudinal or psychological problems are
managed in the hospital. Hence, the population studied is a
large sample of the most difficult patients treated in the area.
The ratio between cases treated at CHM and those treated
at ECHO is around 1:6.
Settings and patients: Cagliari
The study was conducted at Ospedale Brotzu, which is
currently the largest hospital in Sardinia, Italy’s largest
island. The hospital has about 600 beds (22 in the neph-
rology unit) and a transplant center, performing about
50 kidney grafts per year. Cagliari has a population of
about 150,000 inhabitants, which rises to 250,000 if
those living in districts surrounding the city are counted,
and the entire area Ospedale Brotzu serves has a popula-
tion of about 600,000. Nephrology beds are only avail-
able in the hospital. A network of public out-of-hospital
dialysis facilities provides treatment for patients with
lower comorbidity, in keeping with Italian experiences
[13]. The ratio between patients treated at Ospedale
Brotzu and those receiving dialysis in out-of hospital set-
tings is around 1:6.
The dialysis unit has 26 beds dedicated to chronic pa-
tients and 8 for patients with acute kidney injury (AKI)
or chronic kidney disease (CKD), from other Units, re-
quiring hospitalization. The pool of patients on chronic
treatment ranges from 90 to 100, depending up kidney
transplantation, death and transfers. Between 45 and 50
peritoneal dialysis patients are also followed.
Selection criteria
Data were recorded for all patients, but the comparative
analysis considered only the cases receiving dialysis 3
times a week, excluding patients on less or more frequent
treatments, those with particular indications (for example
cardiorenal syndrome), those recovering renal function, or
with a life expectancy of 1 month or less. Data of the ex-
cluded patients are available in table Appendix-1.
Dialysis schedules
Le Mans: the most widely-used technique was post-dilu-
tional on-line hemodiafiltration (HDF), with acetate-free
citrate-based dialysate (calcium concentration 1.5–
1.75 mmol/L; Sodium 138–140 mEq/L, Bicarbonate 32–38,
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Temperature 36–37 °C; Potassium: 2 mmol/L corrected
with potassium infusion in case of need). At time of study,
the prescription followed traditional French guidelines: high
permeability, a surface at least as wide as the patient’s body
surface, reinfusion of at least 24 l per session [14, 15]. Con-
ventional hemodialysis was performed with the same di-
alysate, employing both medium-low and high permeability
dialysers, once more in keeping with the French policy of a
large surface and high-efficiency dialysers. About two thirds
of the patients were dialysed with an arterovenous fistula
(AV fistula), the rest with a permanent tunnelised catheter.
Cagliari: the most widely used technique was hemodialysis
(HD) with bicarbonate-based, acetate-containing dialysate.
About 40% of the patients are on on-line hemodiafiltration
(HDF), 85% post-diluitional. On both techniques, the dialys-
ate used is composed of Sodium 140 mEq/L; Bicarbonate
32 mmol/L, Calcium 1.5 mmol/L, T 36.5 °C, Potassium 2–3
mmmol/L. Polysulfone, high-permeability dialysers are
employed in HD and HDF. Since in Italy the choice of HDF
is aimed principally at improving tolerance and ensuring
hemodynamic stability, the main surfaces employed were
smaller (1.4 and 1.7 m2), and reinfusion volumes lower (10
to 16 l per session). Vascular access was an AV fistula for
about 80% of the patients and a permanent catheter for the
remaining 20%.
Control policies and database
The following general information was gathered for all
cases, in both centers: age, sex, end-stage kidney disease,
vintage of renal replacement therapy and dialysis, educa-
tional level, present and past work, marital status, other
members of household, previous kidney graft or waitlist
for transplantation.
For the sake of the present study, we considered the
data available at the update at the comorbidity and nutri-
tional assessment (Le Mans, July 2016; Cagliari, December
2016) integrated with the information from a previous or
subsequent update, if the patient missed the appointment,
or there were acute clinical problems (for example a fe-
brile illness). Only the patients with at least 2 months of
treatment were included.
The following data, routinely employed in both Cen-
ters, were gathered: creatinine (mg/dL), urea before
and after dialysis (mg/dL), calcium (mmol/L), phosphore
(mmol/L), PTH (pg/ml), 25-OH vitamin D3 (ng/ml), Bi-
carbonate (mmol/L), albumin (g/L), total protein (g/L),
transferrin (g/L), ferritin (micrograms/L), hemoglobin (g/
dl), C-reactive protein (CRP) (mg/dl), total cholesterol
(mg/dl), Brain natriuretic peptide (BNP) (pg/ml), glycated
hemoglobin (%).
Dialysis efficiency was calculated using Daugirdas II
Kt/V, and the patient’s normalized protein catabolic
rate (nPCR) was assessed using the two-point for-
mula; however, in discrepant cases (clinical data
suggesting malnutrition, and calculation indicating a
high PCR), the three-point formula was also calcu-
lated, and the vascular access was examined for evi-
dence of recirculation.
Comorbidity was assessed using the Charlson Index;
to avoid colinearity, the corrected formula suggested for
dialysis patients, that also considers albumin levels, was
not employed in this analysis [16, 17].
Two internationally validated questionnaires were chosen
for nutritional assessment: the Subjective Global As-
sessment (SGA) and Malnutrition Inflammation Score
(MIS) [18, 19].
Statistical analysis
A descriptive analysis was performed as appropriate
(mean and standard deviation for parametric data and
median and range for non-parametric data). Independ-
ent t-test, Chi-square test, Fisher’s test, Mann-Whitney
U test were used, where indicated, for comparisons
between groups. The Anova Test and Kruskal-Wallis
Tests were used for discrete variables. Significance
was set at < 0.05.
A logistic regression analysis was performed between
albumin level and cholesterol level, Kt/V, nPCR, MIS,
age, and Charlson Index. All data were analysed as con-
tinuous parameters. Data were stratified by setting
(Cagliari/Le Mans) and type of dialysis (HD/HDF).
A multivariate analysis considered albumin level
dichotomised at < 3.5 g/dL as the outcome and the pre-
vious parameters as covariates, dichotomised at the me-
dian or at a clinically relevant target level, if near the
median (Kt/V: 1.5, considering adequate dialysis; nPCR:
1 g/Kg/day; cholesterol 200 mg/dL, considered as the
upper normal value, and near the median of our popu-
lation; Charlson Index 7, usually considered as the limit
between high and low comorbidity; MIS 7, near the me-
dian level observed in our population). The analysis
was performed with SPSS software (version 24.0).
Ethical issues
In both centers all the patients treated were adults; all
patients agreed to allow use of their routine clinical and
biochemical data for the sake of this study. Written con-
sent was gathered from all patients, and included con-
sent for data collection and publication; in the case of
language barriers or of intellectual deficits, the patient’s
proxy or legal guardian was asked for permission.
Since the present cross sectional study did not involve
additional blood tests or the use of imaging techniques,
no ethics committee approval was needed in Italy; in
keeping with current French legislation, the study was
approved by the ethics committee in Le Mans (“Avis
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favorable du groupe d’éthique du Centre Hospitalier du
Mans”, 16 mars 2017).
Results
Overall data
Table 1 reports the main baseline data of the patients
treated in the two settings.
The selection of patients on thrice-weekly dialysis,
with a life expectancy of at least one month, without ali-
mentary disorders, including those associated with de-
mentia, excluded 27 patients. Among them were 4 on
once-weekly dialysis, 3 on twice-weekly dialysis, 2 in the
phase of recovery of kidney function (several months
after dialysis start), 14 for very low life expectancy (ter-
minal neoplasia 3 cases; cardiovascular disease in the
others, often with dementia) (Appendix).
There were some relevant baseline differences in the
two populations. The patients in Cagliari, Italy were youn-
ger (67 vs 71 years of age), had a lower BMI (22.6 vs 26.2),
but had a significantly longer treatment vintage (10.3 vs
4.3 years). The Charlson Index, that integrates age, is
significantly higher for Le Mans (9 vs 6) (Table 1).
MIS and cholesterol levels were not significantly dif-
ferent, but BMI was higher and SGA lower in Le
Mans. Conversely, pre-dialysis Blood urea nitrogen
(BUN), Kt/V (Daugirdas II) and nPCR were higher in
Cagliari than in Le Mans.
While both centers offer hemodialysis (HD) and
hemodiafiltration (HDF), HD was the treatment more
frequently chosen in Cagliari, while HDF was the one
more widely employed in Le Mans.
Treatment choice: HD versus HDF
Tables 2 and 3 report the main characteristics of the pa-
tients sorted according to the type of dialysis they re-
ceived (HD or HDF) and to study setting.
In Le Mans HD is primarily chosen for older patients
(an average of almost 10 years older than patients on
HDF), with higher MIS (8 versus 7), in the context of a
very high comorbidity burden (Charlson index 9 in both
Table 1 Overall data of the study population
Study population Study population Le Mans Study population Cagliari P Le Mans vs Cagliari
N 180 97 83 –
Males/Females 59.4%
40.6%
55.7%
44.3%
63.9%
36.1%
0.336
Age median (yrs) (min-max) 69 (18–90) 71 (18–90) 67 (26–89) 0.020
RRT vintage (yrs) (min-max) 6.7 (0.07–43.5) 4.3 (0.07–43.5) 10.3 (0.5–36.9) < 0.001
Charlson median (min-max) 8 (2–16) 9 (2–16) 6 (2–12) < 0.001
MIS median (min-max) 7 (1–27) 7 (1–23) 6 (2–27) 0.020
SGA: A 61.1% 49.5% 74.7% 0.002
SGA: B 33.9% 45.4% 20.5%
SGA: C 5.0% 5.2% 4.8%
HD-HDF (%) HD: 40.0%
HDF: 60.0%
HD: 23.7%
HDF: 76.3%
HD: 59.0%
HDF: 41.0%
< 0.001
BMI Kg/m2 median (min-max) 24.3 (14.6–47.1) 26.2 (16.4–47.1) 22.6 (14.6–31.8) < 0.001
BMI < 20 32 (18.0%) 11 (11.6%) 21 (25.3%) < 0.001
BMI 20–25 66 (37.1%) 26 (27.4%) 40 (48.2%)
BMI 25–30 56 (31.5%) 38 (40.0%) 18 (21.7%)
BMI > = 30 24 (13.5%) 20 (21.1%) 4 (4.8%)
Albumin (g/dl) median (min-max) 3.4 (2.0–4.5) 3.2 (2.6–3.8) 3.7 (2.0–4.5) < 0.001
Albumin < 3 23 (12.8%) 22 (22.7%) 1 (1.2%) < 0.001
Albumin < 3.5 99 (55.0%) 78 (80.4%) 21 (25.3%) < 0.001
BUN (mg/dl) median (min-max) 60.0 (24.4–105) 56.7 (24.4–100) 63.0 (32.0–105) 0.015
Creatinine (mg/dl) median (min-max) 9.1 (2.7–15.0) 8.8 (2.7–15.0) 10.2 (3.6–14.8) 0.003
Cholesterol (mg/dl) median (min-max) 158 (49–263) 162.8 (49–249) 157 (67–263) 0.978
Kt/V median (min-max) 1.6 (0.7–2.3) 1.5 (0.7–2.2) 1.6 (0.8–2.3) 0.005
nPCR (g/Kg/day) median (min-max) 1.04 (0.5–1.8) 0.9 (0.5–1.7) 1.1 (0.6–1.8) 0.002
Legend: RRT renal replacemet therapy, MIS Malnutrition inflammation score, SGA subjective global assessment (A. well nourished, B moderate malnutrition, C
severe malnutrition), HD hemodialysis, HDF hemodiafiltration, BUN blood urea nitrogen (predialysis), Kt/V dialysis efficiency index, according to Daugirdas 2
formula, nPCR normalised protein catabolic rate
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cases); conversely, in Cagliari age is higher on HDF (68.5
versus 65 years) while in both settings the other mea-
sured differences between the HD and HDF populations
are mainly non-significant (Tables 2-3).
Overall, in both settings, Kt/V is at or above target
(overall 1.6); predialysis BUN and creatinine are higher
in Cagliari, in spite of a lower average BMI; nPCR is
lower in Le Mans, but in both settings the levels are
lower than the 1.2 g/Kg/day considered as the “ideal”
target for the overall dialysis population (Tables 1, 2, 3).
Relationship between albumin levels and other
commonly used nutritional markers
Figures 1, 2, 3 report on the association between albu-
min levels and other relevant nutritional parameters in
the overall cohort (Fig. 1), and according to the treat-
ment chosen (Fig. 2: HD, Fig. 3 HDF). The “best fitting”
linear curve is designed for each setting.
There is no significant relationship between albumin
levels, cholesterol and Kt/V in either setting. Conversely,
the relationship between albumin, nPCR, Charlson Index
and age is significant in Cagliari but not in Le Mans, while
the only significant relationship observed in both places is
the link between MIS and albumin levels (p < 001) (Fig. 1).
The figures are similar on HD and HDF (Figs. 2, 3).
No significant relationship was also found between al-
bumin levels, BMI, predialysis urea, creatinine, and
phosphate; conversely, a trend towards lower albumin
levels throughout SGA classes was found (Cagliari: albu-
min level: SGA A: 3.8 (3.1–4.5); B: 3.4 (3.0–4.0); C: 3.4
(2.0–3.8); Le Mans: SGA A: 3.2 (2.6–3.8); B: 3.1 (2.7–
3.8); C: 3.0 (2.8–3.0) p = 0.01 across SGA stages, and p <
0.001 between Cagliari and Le Mans).
Interestingly, the relationship between Kt/V and albu-
min is divergent in Cagliari (statistically significant con-
sensual increase) and in Le Mans, where a paradoxical,
albeit non significant decrease in albumin levels is ob-
served with increasing Kt/V; similarly, the significant in-
crease in albumin we expected would correlate with
nPCR was observed only in Cagliari, while on the con-
trary the line was flat in Le Mans.
Multivariate analysis
The multivariate analysis, shown in Table 4, shows a dif-
ferent pattern in the two settings: in both Charlson Index
above 7 and MIS above 7 correlated with an albumin level
below 3.5 g/dl in the univariate analysis, but the signifi-
cance is retained only in Le Mans for the multivariate ana-
lysis. Conversely, HDF reached statistical significance in
the univariate and multivariate analysis only in Cagliari.
When the two settings are combined, low albumin
levels are highly correlated with MIS, Charlson index and
HDF; however, the highest correlation regards setting of
study, suggesting differences not captured by these “macro”
definitions.
Discussion
The dialysis population is getting older and the com-
plexity of the patients is increasing. In particular in set-
tings such as Italy and France, in which an efficient
out-of-hospital network provides treatment for patients
with lower comorbidity, in-hospital centers follow selec-
tion of the most “difficult cases” [12, 13]. Dialysis choice,
and prescription modulation is obviously crucial; how-
ever, most parameters on which dialysis prescriptions
are modulated are standardised in younger populations,
and in HD, and less is known on the behaviour of the
same parameters in negatively selected cohorts, treated
by different dialysis modalities, such as HDF.
The complexity of the study cohorts is indicated by an
overall median Charlson Index of 8, corresponding to an
expected survival rate of around 30% over 2 years; in the
Table 2 The main dialysis parameters of the study population, according to mode of dialysis (HD versus HDF) and setting of study
HDF Le Mans HDF Cagliari HDF all cases P Le Mans
vs Cagliari HDF
HD Le Mans HD Cagliari HD all cases P Le Mans
vs Cagliari HD
N 74 34 108 – 23 49 72 –
Males/Females 54.1%
45.9%
70.6%
29.4%
59.3%
40.7%
0.104 60.9%
39.1%
59.2%
40.8%
59.7%
40.3%
0.892
Age median (min-max) 69 (31–87) 68.5 (41–87) 69 (31–87) 0.608 78 (18–90) 65 (26–89) 70 (18–90) 0.001
RRT vintage (min-max) 5.2 (0.2–43.5) 9.8 (0.6–34.9) 5.9 (0.2–43.5) 0.001 2.7 (0.1–14.3) 10.8 (0.5–36.9) 7.9 (0.1–36.9) < 0.001
KT/V Daugirdas median
(min-max)
1.6 (0.7–2.2) 1.7 (0.8–2.3) 1.6 (0.7–2.3) 0.013 1.5 (1.2–1.9) 1.6 (0.9–2.3) 1.6 (0.9–2.3) 0.104
nPCR median (min-max) 0.9 (0.5–1.7) 1.1 (0.6–1.5) 0.9 (0.5–1.7) 0.138 1.0 (0.7–1.3) 1.1 (0.6–1.8) 1.1 (0.6–1.8) 0.046
AV fistula, N (%) 61 (82.4%) 27 (79.4%) 88 (81.5%) 0.913 13 (56.5%) 40 (81.6%) 53 (73.6%) 0.049
Hours of dialysis (a) 4 (3–4.5) 4 (3–4.5) 4 (3–4.5) 0.729 4 (2.5–4.0) 4 (3–4.5) 4 (2.5–4.5) 0.942
Intradialytic Weight loss 1.7 (0.1–3.9) 2.2 (0.2–3.1) 2.0 (0.1–3.9) 0.148 1.2 (0.3–3.7) 2.1 (0.9–4.1) 1.9 (0.3–4.1) 0.011
Legend M: RRT Renal replacemet therapy, HD Hemodialysis, HDF Hemodiafiltration, BUN Blood urea nitrogen (predialysis), Kt/V Dialysis efficiency index, according
to Daugirdas 2 formula, nPCR Normalised protein catabolic rate, AV Fistula: arteriovenous fistula
Notea: only cases treated 3 times per week were selected
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Fig. 1 Relationship between serum albumin and other nutritional markers. Note: HD and HDF: statistical significance reached for: Albumin and n
PCR: Cagliari R2 0.228 = r 0.478 P < 0.01; Albumin and Charlson index: Cagliari R2 0.114 = r 0.337 P < 0.01; Albumin and MIS: Le Mans R2 0.213 = r
0.461 P < 0.01; Cagliari R2 0.217 = r 0.466 P < 0.01; Albumin and age: Cagliari R2 0.166 = r 0.407 P < 0.01
Fig. 2 Relationship between serum albumin and other nutritional markers: patients on hemodialysis. Note: HD: statistical significance reached for:
Albumin and nPCR: Cagliari R2 0.184 = r 0.429 P < 0.01; Albumin and MIS: Le Mans R2 0.399 = r 0.632 P < 0.01; Cagliari R2 0.205 = r 0.452 P < 0.01;
Albumin and age: Cagliari R2 0.116 = r 0.341 P < 0.05
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context of high cormorbidity, age and Charlson index
were higher in Le Mans (9 in Le Mans versus and 6
in Cagliari), vintage of renal replacement therapy, a
further important survival marker, was higher in
Cagliari (10.3 years in Cagliari vs 4.3 years in Le
Mans) (Tables 1, 2, 3) [20, 21].
There are two main result of our study of potential
clinical relevance.
The first point is that, at difference with what has been
described in large, non selected dialysis population,
mainly on HD, in our high-comorbidity, elderly dialysis
populations, with high dialysis efficiency (median Dau-
girdas 2 Kt/V: 1.6) the relationship between the different
markers of comorbidity, nutrition and dialysis efficiency
is not a close one [22–25]. In particular neither Kt/
V, nor albumin levels were strictly correlated with
BMI, cholesterol levels and n-PCR. Furthermore, we
did not find a correlation between dialysis efficiency,
MIS or SGA and Charlson index, while only the
composite MIS was highly correlated with albumin
levels (Figs. 1, 2, 3). The correlation is probably not
explained by colinearity (MIS integrates albumin, but
albumin level accounts for only 10% of the malnutri-
tion inflammation score).
The second point regards the two main survival and treat-
ment markers, Kt/V (efficiency) and albumin (nutrition). In
our study, their relationship was context sensitive: Kt/V
shows a significant direct correlation with albumin level in
Cagliari, and a non-significant inverse correlation in Le
Mans (Figs. 1, 2, 3). Interestingly, no correlation was found
between nPCR and albumin level in Le Mans while a
direct correlation was found in Cagliari. This pattern
strongly suggests that differences in prescriptions
have a nearly opposite effect on albumin level. Since
HDF in Le Mans is performed with large dialysers
and high convective volume, the inverse relationship
with Kt/V supports a crucial role of albumin loss. Al-
bumin loss is a well-known effect of HDF, but its
clinical role is often considered as minor, while our
study suggests that the effect be highly relevant in
the elderly dialysis population. Quantification of al-
bumin loss by direct analysis of the dialysate, to-
gether with analysis of markers of hepatic synthesis,
may be a next step to guide dialysis choice avoiding
hypoalbuminemia [26–31].
The multivariate analysis confirms the association of
patient-related measures (Charlson Index, MIS) with al-
bumin levels, dichotomised at 3.5 g/dl, and the odds ra-
tio of low albumin level is significantly higher for HDF,
in keeping with the interpretation of a central role for al-
bumin loss (Tables 4-5). The association between the
study setting and albumin levels is the most significant
one in the multivariate analysis, which adjusted for all
the previous covariates. This suggests that merely
Fig. 3 Relationship between serum albumin and other nutritional markers: patients on hemodiafiltration. Note: HDF: statistical significance
reached for: Albumin and nPCR: Cagliari R2 0.234 = r 0.484 P < 0.01; Albumin and Charlson index: Cagliari R2 0.243 = r 0.493 P < 0.01; Albumin and
MIS: Le Mans R2 0.173 = r 0.416 P < 0.01; Cagliari R2 0.242 = r 0.492 P < 0.01; Albumin and age: Cagliari R2 0.237 = r 0.487 P < 0.01
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identifying the treatment used (HD or HDF) is not suffi-
cient and that profoundly different treatments are
grouped under the same label (Table 5).
The limits of this study are many. The populations, al-
though studied in detail, were relatively small; we stud-
ied the relationship between parameters assessed at a
single time, while trajectories are probably more sensi-
tive outcome markers.
While the multivariate approach accounts, at least par-
tially, for the baseline differences, the populations were
not homogeneous, thus creating the risk of colinearity in
some measures; in particular, the population in Cagliari
was younger, with higher prevalence of AV fistula; the
higher predialysis BUN and creatinine in Cagliari may
the expression of a better preserved nutritional state, not
completely accounted for by the stratification for age.
Furthermore, as cited, some degree of colinearity links
albumin and MIS, although albumin accounts for only
10% of MIS score.
The decision to consider only inexpensive, routine
markers, means that other important markers or ana-
lyses, such as prealbumin or bioimpedance analysis, not
yet routinely used in clinical practice, were not consid-
ered, but will be required to interpret our data.
These limitations stress the need to interpret with cau-
tion the usual nutritional markers in high-risk dialysis
patients [32].
Indeed, the relationship between the most studied marker
of nutrition, serum albumin, and the other markers of dia-
lysis care may be less strict than previously described, at
least in high comorbidity populations and the dialysis tech-
nique may interfere with results.
Our study therefore suggests that we need to further
refine our knowledge by studying cohorts stratified ac-
cording to a detailed dialysis prescription, including
more markers and analyses, so that the roles played by
patients’ innate characteristics and treatment-related
components can be more clearly discerned.
Conclusions
In elderly, high comorbidity dialysis population,
treated by HD and HDF, and in which dialysis effi-
ciency target is met, the correlations among the clas-
sic efficiency and nutrition markers, well described in
younger populations on HD, is weak or absent. After
Table 4 Univariate and multivariate logistic regression analysis
in each setting of study: outcome: albumin level < 3.5 g/dL
UNIVARIATE
OR (CI 95%)
MULTIVARIATE
OR (CI 95%)
CAGLIARI (83 patients)
HD 1 1
HDF 5.658 (1.902–16.826) 8.683 (2.349–32.101)
KT/V Daugirdas < 1.5 1 1
KT/V Daugirdas> = 1.5 0.944 (0.315–2.834) 0.762 (0.197–2.945)
nPCR Daugirdas < 1 1 1
nPCR Daugirdas > = 1 0.239 (0.084–0.678) 0.366 (0.096–1.390)
Cholesterol < 150 mg/dL 1 1
Cholesterol > = 150 mg/dL 0.849 (0.314–2.290) 1.076 (0.300–3.858)
Charlson < 7 1 1
Charlson > = 7 2.955 (1.062–8.217) 3.094 (0.826–11.591)
MIS < 7 1 1
MIS > = 7 4.881 (1.653–14.417) 3.651 (0.891–14.962)
LE MANS (97 patients)
HD 1 1
HDF 0.828 (0.245–2.799) 1.225 (0.293–5.126)
KT/V Daugirdas < 1.5 1 1
KT/V Daugirdas > = 1.5 1.200 (0.438–3.286) 1.822 (0.523–6.351)
nPCR Daugirdas < 1 1 1
nPCR Daugirdas > = 1 0.733 (0.268–2.001) 0.585 (0.159–2.151)
Cholesterol < 150 mg/dL 1 1
Cholesterol > = 150 mg/dL 1.056 (0.381–2.925) 0.975 (0.305–3.114)
Charlson < 7 1 1
Charlson > = 7 4.945 (1.602–15.263) 4.285 (1.129–16.263)
MIS < 7 1 1
MIS > = 7 7.500 (2.261–24.881) 8.451 (2.292–31.161)
Legend M males, F females, MIS Malnutrition inflammation score, SGA
subjective global assessment (A. well nourished, B moderate malnutrition,
C severe malnutrition), HD hemodialysis, HDF hemodiafiltration, BMI body
mass index, Hb haemoglobin, CRP C reactive protein, PTH parathyroid
hormone, BNP blood natriuretic peptide
Data in bold are statistically significant
Table 5 Univariate and multivariate logistic regression analysis:
outcome: albumin level < 3.5 g/dL
UNIVARIATE
OR (CI 95%)
MULTIVARIATE
OR (CI 95%)
HD 1 1
HDF 4.092 (2.173–7.703) 3.592 (1.466–8.801)
KT/V Daugirdas < 1.5 1 1
KT/V Daugirdas> = 1.5 0.715 (0.386–1.326) 1.131 (0.473–2.703)
nPCR Daugirdas < 1 1 1
nPCR Daugirdas > = 1 0.337 (0.181–0.626) 0.552 (0.240–1.272)
Cholesterol < 150 mg/dL 1 1
Cholesterol > = 150 mg/dL 1.039 (0.572–1.887) 1.030 (0.451–2.350)
Charlson < 7 1 1
Charlson > = 7 6.545 (3.329–12.871) 3.153 (1.311–7.582)
MIS < 7 1 1
MIS > = 7 4.690 (2.492–8.825) 5.916 (2.457–14.241)
CAGLIARI 1 1
LE MANS 12.120 (5.992–24.517) 7.155 (2.955–17.324)
Legend HD hemodialysis, HDF hemodiafiltration, MIS Malnutrition
inflammation score, Kt/V dialysis efficiency index, according to Daugirdas 2
formula, nPCR normalised protein catabolic rate, Charlson Charlson index
Data in bold are statistically significant
Piccoli et al. BMC Nephrology  (2018) 19:171 Page 9 of 11
correction for comorbidity and treatment, the setting
of study was significantly related to albumin levels;
this sensitivity to context emphasizes the importance
of subtle differences in dialysis prescriptions, indir-
ectly suggesting that fine modulation of dialysis
schedules may be a tool for controlling albumin
levels, and perhaps improving nutritional status, in
fragile dialysis patients.
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